➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Merck
Baxter
Johnson and Johnson
Medtronic

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,052,314


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,052,314 protect, and when does it expire?

Patent 10,052,314 protects ERLEADA and is included in one NDA.

This patent has fifty-seven patent family members in thirty-one countries.

Summary for Patent: 10,052,314
Title:Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
Inventor(s): Chen; Isan (San Diego, CA)
Assignee: Aragon Pharmaceuticals, Inc. (San Diego, CA)
Application Number:15/851,444
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 10,052,314

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) ⤷  Free Forever Trial
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,052,314

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013323861 ⤷  Free Forever Trial
Australia 2018206695 ⤷  Free Forever Trial
Australia 2020244431 ⤷  Free Forever Trial
Brazil 112015006705 ⤷  Free Forever Trial
Canada 2885415 ⤷  Free Forever Trial
Chile 2015000715 ⤷  Free Forever Trial
China 104661658 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
McKesson
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.